Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) hit a new 52-week high during trading on Wednesday after the company announced better than expected quarterly earnings. Weiss Ratings reiterated a “hold (c)” rating on shares of ACADIA Pharmaceuticals in a research note on Wednesday, July 29th. Thompson sold 16,558 shares of ACADIA Pharmaceuticals stock in a transaction on Thursday, July 30th. Meeder Asset Management Inc. bought a new position in ACADIA Pharmaceuticals during the fourth quarter valued at approximately $26,000. ACADIA Pharmaceuticals Company Profile(Get Free Report)ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders.